Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvolvE
2024-512767-30-00Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Barzolvolimab with Placebo (2 arms). Primary endpoint: Absolute change from baseline to Week 12 in the PMC/high power field (hpf). Started Sep 2023; status: completed.
02
Drugs
barzolvolimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2024-512767-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512767-30-00.